AstraZeneca and VaxEquity partner to advance RNA therapeutics
VaxEquity will receive development, approval and sales-based milestone payments of up to $195m from AstraZeneca.
Diseases
Novavax and SII seek WHO emergency use listing for Covid-19 vaccine
WHO authorisation is a prerequisite to supply the vaccine to several countries that are part...
Tonix and Columbia University to develop specialised Covid-19 vaccines
The alliance plans to isolate therapeutically significant fully human neutralising monoclonal antibodies against Covid-19.
Prescription drugs in oncology reach peak sales five to seven years post-launch
The most lucrative geographies for new oncology drugs seem to be those in which peak...
Immunic signs agreement to in-license assets to treat viral infections
A combination of DHODH inhibitor, IMU-838 and N4-hydroxycytidine offered a decline in viral RNA to...
AbCellera and Everest enter deal to discover antibody therapies
Everest will make research, milestone and royalty payments to AbCellera for the products developed through the collaboration.
FDA approves Pfizer Covid vaccine booster shot for older population
A third vaccine dose is intended for people at high risk and those prone to institutional or occupational exposure to the virus.
Boehringer acquires Abexxa Biologics to develop new cancer treatments
Through the acquisition, Boehringer will now have access to Abexxa’s expertise in targeting cancer-specific proteins.
Lilly signs deal to supply Covid-19 antibody combo to European countries
On obtaining approval in Europe, participating nations in the EU and EEA can buy the antibodies directly from Lilly.
J&J’s data confirms robust and durable protection of Covid-19 vaccine
Antibody levels increased to 12-fold after four weeks of administering a booster shot of the vaccine, the study showed.
Amgen wins lawsuit against Sandoz and Zydus for Otezla patent
Otezla is approved to treat adults with plaque psoriasis, active psoriatic arthritis and oral ulcers linked with Behçet’s disease.
